Treatmentwith the biologic drug improved depression (33.6 and 45.2% of patients treated withixekizumab at 80 mg/4weeks and 80 mg/2 weeks, respectively) and decreased serum levels ofC-reactive protein (sCRP; 23.3 vs. 27.4% patients with sCRP levels still >5 mg/L), thussuggesting that both inflammatory markers and IL-17A may be involved in Ps comorbiddepressive patients. This evidence concerns the gene IL17A and major depressive disorder.